SELLAS Life Sciences Group, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $19.15
- 52-Week Range
- $1.39 – $24.89
- Market Cap
- $3.66B
- P/E (TTM)
- —
- EPS (TTM)
- -0.20
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 27.70
- PEG Ratio
- —
- Return on Equity
- -40.31%
- Return on Assets
- -24.23%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 14.92
- Debt/Equity
- 0.00
- Total Debt
- $599.00K
- Free Cash Flow
- $-14.92M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $3.53B
Market Snapshot
About
SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company developing novel cancer immunotherapies. The company focuses on therapies targeting acute myeloid leukemia and other blood cancers. Its lead product candidate is galinpepimut-S, a cancer immunotherapy designed to stimulate immune responses against malignant cells.